CAPR News and Press, Capricor Therapeutics Inc. From 05/13/19

Capricor Therapeutics (NASDAQ: CAPR ): Q1 GAAP EPS of -$0.08 beats by $0.03 . More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development o...

LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its ...

Gene therapy developer Audentes Therapeutics (NASDAQ: BOLD ) has expanded its pipeline with new programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). More news on: Audentes Therapeutics, Inc., Sarepta Therapeutics, Inc., Solid Biosciences Inc., Healthcare sto...

Capricor Therapeutics, Inc. (CAPR) Q4 2018 Earnings Conference Call March 28, 2019 16:30 ET Corporate Participants AJ Bergmann - Chief Financial Officer Linda Marbán - President & Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim Group Joe...

Capricor Therapeutics (NASDAQ: CAPR ): Q4 GAAP EPS of -$0.11 beats by $0.05 . More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of ...

LOS ANGELES, March 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report it...

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...

LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients already enrolled in its HOPE-2 clinical trial of CAP-1002, the company’s novel cell the...